Chesley Taft & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Chesley Taft & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,560	Closed	-$644K	–	239
2015 Q2	$644K	Sell	3,560 -50	-1%	-$8.63K	0.07%	163
2015 Q1	$626K	Sell	3,610 -1,693	-32%	-$306K	0.06%	169
2014 Q4	$981K	Buy	5,303 +35	+0.7%	+$6.49K	0.1%	142
2014 Q3	$874K	Hold	5,268	–	–	0.09%	149
2014 Q2	$823K	Sell	5,268 -282	-5%	-$44.5K	0.09%	153
2014 Q1	$844K	Sell	5,550 -945	-15%	-$150K	0.09%	153
2013 Q4	$863K	Hold	6,495	–	–	0.09%	170
2013 Q3	$754K	Buy	6,495 +25	+0.4%	+$2.74K	0.08%	172
2013 Q2	$597K	Buy	+6,470	New	+$623K	0.07%	195

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Chesley Taft & Associates's ALXN Position: Q3 2015 in Review

Chesley Taft & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 3,560 shares — an estimated $644K sold.

Chesley Taft & Associates first reported a position in ALXN in Q2 2013 and held it in 9 quarters. The position peaked at $981K in Q4 2014. 515 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

Chesley Taft & Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Chesley Taft & Associates sold 3,560 Alexion Pharmaceuticals shares in Q3 2015, an estimated $644K.
Chesley Taft & Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Chesley Taft & Associates's Alexion Pharmaceuticals position peaked at $981K in Q4 2014.
515 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Chesley Taft & Associates's 13F filing for Q3 2015, filed 29 Oct 2015.